Rocket Pharmaceuticals, Inc. (RCKT): Is This Gene Therapy Stock a Good Buy Right...

Published on 29 Dec 2024 on Insider Monkey · via Yahoo Finance

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we...

Read the rest of the article

Start tracking your investments with Statfolio

We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article,...

Insider Monkey · via Yahoo Finance 29 Dec 2024

We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, w...

Insider Monkey · via Yahoo Finance 21 Nov 2024

On Monday, Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) presented long-term safety and efficacy...

Benzinga · via Yahoo Finance 19 Nov 2024

Researchers at Children’s Hospital of Philadelphia (CHOP) announced encouraging results from the...

Newswise 18 Nov 2024

FDA Rejects Rocket Pharmaceuticals' Gene Therapy For Rare Immune Disorder, Asks For More Data, St...

Benzinga · via Yahoo Finance 20 Jun 2024

Rocket Pharmaceutical RCKT reported a loss of 66 cents per share in the first quarter of 2024, na...

Zacks via Yahoo Finance 7 May 2024

Baron Funds, an investment management company, released its “Baron Health Care Fund” first quarte...

Insider Monkey via Yahoo Finance 24 Apr 2024

Rocket Pharmaceuticals RCKT announced that the EMA accepted the marketing authorization applicati...

Zacks via Yahoo Finance 3 Apr 2024

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quart...

Insider Monkey via Yahoo Finance 22 Jan 2024

With the business potentially at an important milestone, we thought we'd take a closer look at Ro...

Simply Wall St. via Yahoo Finance 15 Jan 2024